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Abstract
Background: High doses of anti-inflammatory drugs, such as aspirin and salicylates, improve glucose metabolism in insulin
resistant and type 2 diabetic patients. It has also been shown that the glucose lowering effect is related to the unspecific
ability of these drugs to inhibit inhibitor kinaseb (IKKb). In this study we have investigated the effect of a selective IKKb-
inhibitor on beta cell survival and the prevention of diet induced type 2 diabetes in the gerbil Psammomys obesus (P.
obesus).
Methodology/Principal Findings: P. obesus were fed a diabetes inducing high energy diet for one month in the absence or
presence of the IKKb-inhibitor. Body mass, blood glucose, HbA1C, insulin production and pancreatic insulin stores were
measured. The effects on beta cell survival were also studied in INS-1 cells and primary islets. The cells were exposed to IL-1b
and subsequently reactive oxygen species, insulin release and cell death were measured in the absence or presence of the
IKKb-inhibitor. In primary islets and beta cells, IL-1b induced the production of reactive oxygen species, reduced insulin
production and increased beta cell death, which were all reversed by pre-treatment with the IKKb-inhibitor. In P. obesus the
IKKb-inhibitor prevented the development of hyperglycaemia and hyperinsulinaemia, and maintained pancreatic insulin
stores with no effect on body weight.
Conclusions/Significance: Inhibition of IKKb activity prevents diet-induced diabetes in P. obesus and inhibits IL-1b induced
reactive oxygen species, loss of insulin production and beta cell death in vitro.
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Introduction
Obesity is characterised by a state of low-grade inflammation
[1–3], which may contribute to the development of insulin
resistance and type 2 diabetes [3,4]. Type 2 diabetes is
characterized by insulin resistance, pancreatic beta cell dysfunc-
tion and reduced beta cell mass [5]. Although interventions that
reduce inflammatory parameters have been associated with
improved insulin and glucose metabolism during insulin resistance
and type 2 diabetes [2,6], the mechanisms connecting inflamma-
tion and diabetes are still unclear.
Inflammatory processes are characterised by the migration of
proliferating white blood cells from the circulation to the tissues
and activated macrophages and cytokines released from the
adipose tissue have been associated with insulin resistance [7,8].
Whereas TNFa has been associated with peripheral insulin
resistance [3], islet inflammation and increased beta cell death
have in particular been associated with the cytokine IL-1b [9,10].
IL-1b may be produced by beta cells themselves or by homing
macrophages within the pancreas. The involvement and thera-
peutic potential of IL-1b in the treatment of type 2 diabetes was
recently demonstrated by treatment with the IL-1b receptor
antagonist Anakinra, which resulted in improved beta cell
secretory function and glycaemia control in human type 2 diabetic
patients [11].
The transcription factor nuclear factor-kappa-B (NFkB) is
central in the regulation of inflammatory responses and control
of the innate immune system [12,13]. Both TNF-a and IL-1b
stimulate NFkB activation. NFkB is activated by a protein
complex, where interaction between the inhibitor kinase (IKK)
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(IkB) protein. IkB is subsequently ubiquitinated and targeted for
degradation by the proteasome, allowing release and translocation
of NFkB to the nucleus and subsequent gene transcription [14,15].
In animal models, the lack of IKKb in immune cells protects the
animals from insulin resistance during High fat feeding [16]. It has
also been shown that the anti-inflammatory drug salicylate
improves insulin resistance in diabetic rodents as well as glycaemia
in obese and diabetic patients, at least in part, through the
inhibition of the NFkB pathway [17,18].
In most cell-types regulation of inflammatory pathways is
associated with the induction of oxygen-derived free radicals, often
referred to as reactive oxygen species (ROS). Increased ROS
production has been demonstrated to be a unifying mechanism in
endothelial cell dysfunction and late diabetic complications [19].
Additionally, ROS seems to be associated with insulin resistance in
adipocytes, as normalisation of ROS levels reverses the inflam-
matory response and increases insulin sensitivity of these cells [20].
Observations in beta cells have shown that IL-1b mediated toxicity
is in part mediated through induced production of reactive oxygen
species in particular nitric oxide (NO) [21,22].
We have utilized the gerbil Psammomys obesus (P. obesus) in our
studies, as it is a rodent model of nutritionally induced type 2
diabetes. When transferred from their normal low-calorie saltbush
diet to a more energy rich diet (regular rodent laboratory chow)
the majority of the animals develop diabetes within a few weeks
[23,24]. This animal model is characterized by a fast depletion of
insulin stores as a diabetic phenotype develops [24]. Similar to
humans, these animals display increased pancreatic inflammation
and associated beta cell death [9,25].
The aim of the present study was to evaluate if inhibition of the
IKKb and NFkB pathways could prevent 1) IL-1b mediated beta
cell toxicity in vitro and 2) diet induced diabetes in vivo. This was
done using a selective IKKb-inhibitor originally developed against
steroid-resistance asthma [26].
Results
Inhibition of the NFkB pathway inhibits IL-1b induced
beta cell failure in INS-1 cells
We first tested our hypothesis that inhibition of the NFkB
pathway with the IKKb-inhibitor would rescue beta cells against
IL-1b-induced toxicity. This was done in INS-1 cells by measuring
viability and apoptosis during IL-1b exposure. Forty-eight hours of
IL-1b exposure reduced mitochondrial activity around two-fold
(fig. 1A) in parallel with an increased caspase 3/7 activity (fig. 1B).
Co-incubation with the IKKb-inhibitor completely restored
mitochondria activity and significantly reduced caspase 3/7
activity.
Since previous observations in beta cells have shown that IL-1b
mediated beta cell destruction is in part mediated through nitric
oxide (NO) production [27], we also measured expression levels of
inducible nitric oxide synthase (iNOS). As expected iNOS
transcription was massively induced in response to 24 hours IL-
1b exposure, which was fully prevented by co-incubation with the
IKKb-inhibitor (Fig. 1C).
Figure 1. Prevention of IL-1 mediated beta cell toxicity in INS-1 cells by an IKKb-inhibitor. Rat insulinoma (INS-1) cells were incubated in
the presence and absence of IL-1b and the IKKb-inhibitor for 48 hours. A: mitochoiondrial activity, a measurement of viability was determined by the
MTT assay (Promega, USA). B: Cell death was measure as caspase 3/7 activity. C: iNOS mRNA expression was quantified using RT-PCR after cells had
been incubation for 24 hours in the presence and absence of IL-1b and the IKKb-inhibitor. D: Accumulated Insulin in the media was measured after
48 hours incubation in the presence or absence of IL-1b and the IKKb-inhibitor. E: GSIS was performed after 48 hours incubation in the presence or
absence of IL-1b and the IKKb-inhibitor. All data are shown as the mean 6 S.E.M. (*p,0,05; **p,0,01; ***p,0,001).
doi:10.1371/journal.pone.0013341.g001
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induced loss of insulin secretion, accumulated and GSIS were
measured. This was done after 48 hours incubation in the absence
or presence of IL-1b and with or without the IKKb-inhibitor. As
seen from fig. 1D accumulated insulin production was halted by
IL-1b exposure, but completely unaffected when the IKKb-
inhibitor was also present. Analysis of GSIS in control cells
demonstrated a more than three-fold induction (8,2 vs. 26,1 ng/ml
insulin) (Panel E). Cells exposed to IL-1b for 2 days displayed a
diminished insulin production at both basal glucose (Panel E white
columns, although non-significant) and followed stimulation at high
glucose (Panel E. black columns). Co-incubation with the IKKb-
inhibitor significantly protected the cells against the IL-1b-induced
decrease in insulin secretion (16,1 vs. 6,2 ng/ml insulin).
IL-1b induced radical formation prevented by the
IKKb-inhibitor
To further characterize the effects of IL-1b on INS-1 cells, the
production of radical formation was measured by H2DCFDA.
H2DCFDA is normally referred to as an indicator of ROS despite
its affinity for both reactive oxygen and nitrogen species (Table 1)
[28]. We confirmed and extended previous observations demon-
strating that that IL-1b exposure caused the level of ROS to rise in
a time and concentration dependent manner with maximal
production after 24 hours (Fig. 2A). Co-incubation with the
IKKb-inhibitor reduced the ROS production in a dose-dependent
manner (Fig. 2B). 0,5 mM of the IKKb-inhibitor attenuated the
effect of 50 pg/ml IL-1b whereas a double dose, 1 mM was
required to inhibit the effect of the 150 pg/ml IL-1b treatment. A
macroscopic examination revealed that not only a subpopulation
of dividing cells, but all cells were affected by the treatments
(Fig. 2C).
Effect of IL-1b and the IKKb-inhibitor using primary
newborn rat islets
To evaluate if the effects observed in the INS-1 beta cell line
could be observed in primary beta cells, we isolated newborn rat
islets and exposed them to IL-1b in the absence or presence of the
IKKb-inhibitor. We found that IL-1 b increased the production of
ROS by more than two-fold and this effect was attenuated by by
the IKKb-inhibitor (fig. 3A). In parallel, iNOS expression was
significantly up-regulated in IL-1b, which was prevented by the
NFkB pathway inhibitor (Fig. 3B).
Effects of IL-1b and IKKb-inhibition on islets of
Langerhans isolated from P. obesus
To evaluate the in vivo potential of the IKKb-inhibitor in the
prevention of type 2 diabetes, the animal model P. obesus was
selected. First we established the effects of the mouse IL-1b and the
IKKb-inhibitor on islets isolated from healthy adult animals. We
measured the production of ROS and insulin following IL-1b
exposure with or without co-incubation with the IKKb-inhibitor.
Exposure to IL-1b for 24 hours increased the production of ROS,
which was attenuated by the inhibitor (fig. 4A). At basal glucose
insulin secretion was not different between control islets and islets
exposed to IL-1b or the IKKb-inhibitor (fig. 4B white columns).
However, at high glucose (fig. 4B black columns) IL-1b significantly
Table 1. Fluorescence response of H2DCFDA to various
reactive oxygen and reactive nitrogen species [28].
Reactive oxygen or
nitrogen species H2DCF affinity (%)
Hydroxyl radical (HO?) 100
Peroxynitrite anion (ONOO
–)8 9
Peroxyl radical (ROO?)1 0
Hydrogen peroxide (H2O2)3
Nitric oxide (NO) 2
Hypochlorite anion (
–OCl) 1
Superoxide anion (?O2
–)1
Singlet oxygen (1O2) 0,4
doi:10.1371/journal.pone.0013341.t001
Figure 2. Prevention of IL-1 mediated ROS in INS-1 cells by an
IKKb-inhibitor. A: ROS was measured in Krebs-Ringer bicarbonate
buffer with 10 mM fluorescent probe CM-H2DCFDA (Molecular probes)
following incubation of the cells with and without IL-1b for 4, 8, 16 and
24 hours. Results are shown as delta fluorescence (t 90 min – t45 min).
B: ROS was measured after 24 hours incubation in the presence or
absence of IL-1b and the IKKb-inhibitor. C: Microscopy of INS-1 after
24 hours incubation in the presence or absence of IL-1b and the IKKb-
inhibitor (magnification x10). Phase contrast (upper photos) and
fluorescence (lower photos) after incubation with 10 mM fluorescent
probe (CM-H2DCFDA). All data are shown as the mean 6 S.E.M.
(*p,0,05; **p,0,01; ***p,0,001).
doi:10.1371/journal.pone.0013341.g002
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was significantly attenuated in the presence of the IKKb-inhibitor
(19,5 vs. 7,2 ng/ml insulin).
IKKb-inhibition prevents diet induced diabetes in P.
obesus
We next examined if inhibition of the NFkB pathway could
prevent diet induced diabetes. We used the diabetes prone P. obesus
on a high energy diet treated with vehicle or 60 mg/kg/day
IKKb-inhibitor for 28 days. As seen in fig. 5A the inhibitor
treatment had no effect on body weight gain. Vehicle treated
animals developed diet induced diabetes during the 28 days on a
high-energy diet (fig. 5B). Within one week the animals had a
significant increase in non-fasting BG levels (from 3,4 mM at day
one to above 10 mM at day 7 (p,0,001)), which was further
increased to more than 15 mM by day 28. Hyperglycaemia was
accompanied by a significant increase in HbA1C (fig. 5C), with an
average of 4,860,1% at day zero compared to 6,460,3% at day
28 (p,0,001). Vehicle treated animals significantly increased
plasma insulin levels until day 21 where hyperinsulinaemia was
declining (fig. 5D) (day 1: 1,360,1 nM vs. day 21: 6,860,9 nM;
p,0,001; day 28: 5,660,7 nM). Animals treated with the IKKb-
inhibitor showed no signs of diet induced diabetes during the 28
days on a high-energy diet. The levels of HbA1C (fig. 5C), BG
(fig. 5B), and plasma insulin (fig, 5D) were significantly lower than
the vehicle treated control animals and did not show a significant
increase from day 0 to day 28.
To further evaluate the effects of treatment on beta cell function
and capacity, we stained for insulin and measured total insulin
content in acid ethanol extracts of pancreas from animals treated
for 28 days with vehicle or the IKKb-inhibitor in addition to age
matched non-diabetic animals. As seen in figure 6A we found an
inverse correlation between pancreatic insulin content and blood
glucose. Furthermore, the treatment had a significant effect on
pancreatic insulin supply, as reflected by a more than three-fold
increase of pancreatic insulin content in animals treated with the
IKKb-inhibitor compared to the vehicle treated animals (day 28:
IKKb-inh. 2667,2 mg vs. vehicle 761,5 mg; p,0,05). After 28
days on high energy diet insulin stainings also showed that most
beta cells barely expressed insulin (fig. 6B). However, animals
treated with the IKKb-inhibitor showed clear and dense insulin
staining of most beta cells (fig. 6C), which were comparable with
insulin staining of beta cells in non-diabetic lean controls animals
(fig. 6D).
Discussion
The transcription factor NFkB is a ‘‘master switch’’ in
inflammatory processes. NFkB is found in almost all cell types
and is involved in cellular responses to stimuli such as stress,
cytokines, free radicals, ultraviolet irradiation, oxidized LDL, and
bacterial or viral antigens. A connection between inflammation,
islet function and type 2 diabetes has been found. Non-specific
inhibitors of the NFkB pathway, including aspirin and aspirin-
related drugs, have shown positive therapeutic effects in diabetic
patients, indicating the importance of NFkB activation in the
development of type 2 diabetes [2,6,17,18,29].
As beta cell dysfunction and death in type 2 diabetes has been
associated with cytokine-induced radical formation [25], we
incubated INS-1 cells, rat islets and P. obesus islets with IL-1b
and measured free radical formation, beta cell function and beta
cell death. In isolated beta cells and islets, IL-1b increased the
production of free radicals significantly, which was reflected in a
loss of insulin production and beta cell death. In beta cells, IL-1b-
induced free radical formation was shown in a time and dose
dependent manner, with maximum production after 24 hours. IL-
1b induced beta cell death has been associated with increased
Figure 3. Prevention of IL-1b mediated ROS in newborn rat
islets of Langerhans by an IKKb-inhibitor correlates with
transcription of iNOS. A: In newborn rat islets ROS was measured
after 24 hours incubation in the presence or absence of IL-1b and the
IKKb-inhibitor. B: iNOS mRNA expression was quantified using RT-PCR
after the islets had been incubation for 24 hours in the presence and
absence of IL-1b and the IKKb-inhibitor. All data are shown as the mean
6 S.E.M. (*p,0,05; **p,0,01; ***p,0,001).
doi:10.1371/journal.pone.0013341.g003
Figure 4. Islets from P. obesus are rescued from of IL-1b induced ROS production and diminished insulin production by an IKKb-
inhibitor. A: Islets from healthy adult P. obesus were incubated in the presence and absence of L-1b and the IKKb-inhibitor for 24 hours before ROS
was measured. B: GSIS was performed after 6 days incubation in the present or absent of IL-1b and the IKKb-inhibitor. All data are shown as the mean
6 S.E.M. (*p,0,05; **p,0,01; ***p,0,001).
doi:10.1371/journal.pone.0013341.g004
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with beta cell death, is iNOS. iNOS is primarily responsible for the
production of NO radicals [21,22], and is normally silent, however
IL-1b treatment induces a significant induction of the iNOS
mRNA expression. We found that IL-1b up-regulated the
expression of iNOS by greater than 500-fold in both beta cells
and islets. IL-1b induced iNOS transcription, radical formation,
loss of insulin production and beta cell death were all reversed by
the IKKb-inhibitor, indicating a link between iNOS activity,
radical formation, beta cell function and death. A tight redox
balance is important for the beta cell since it is weakly protected
against oxidative damage, as a result of low levels of the defense
proteins superoxide dismutase and glutathione peroxidise [30,31].
There are many reactive species, each with various harmful effects.
One example is the superoxide radical (O2*-), which is produced
continuously as a by-product of oxidative phosphorylation, but is
not very reactive. Similar to superoxide, the NO radical reacts
slowly, however, when the two are combined together they form
the highly toxic peroxynitrite radical (ONOO
2) [32]. The probe
used in our study to quantify radical formation has a low affinity
for both NO and superoxide compared to peroxynitrite, and since
peroxynitrite effectively oxidizes proteins, lipids and DNA, it is
likely that IL-1b induced radicals caused beta cell failure and
ultimately beta cell death.
P. obesus is a well established model of diet induced type 2
diabetes. When these animals are switched from low caloric density
diet to a high caloric density diet they rapidly develop obesity,
hyperglycaemia and hyperinsulinaemia [24,33]. In this study, a
high-energy diet resulted in a rapid rise in insulin levels in the
vehicle treated animals. However, the higher level of insulin was not
sufficient to maintain normal blood glucose control as both BG and
subsequently HbA1C continued to rise. After three weeks of a high-
energy diet there was a decrease in insulin levels and a further
deterioration in BG control. Loss of insulin production is expected
Figure 5. IKKb inhibition prevents diet induced diabetes in P. obesus. Diabetes-prone male and female P. obesus, age of 13–14 weeks, were
transferred from ad libitum low energy diet to ad libitum high energy diet. At the same day (day 0) treatment was initiated with vehicle (open circles
n=12) or with the IKKb-inhibitor (black circles n=10). A: Body weight was measured daily. B: Non fasting blood glucose was measured twice weekly.
C: HbA1c was measured once weekly. D: Insulin was measured at day 0, 11 and then twice a week through the rest of the study. All data are shown as
the mean 6 S.E.M. (*p,0,05; **p,0,01; ***p,0,001).
doi:10.1371/journal.pone.0013341.g005
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destruction reported during the late stage of diabetes development
in this animal model [24,25,33]. In animals treated with the IKKb-
inhibitor,thehigh-caloriediet onlyresulted ina transientincreasein
BG. However, a small counter-regulatory increase in insulin
production was sufficient to prevent an incipient hyperglycaemia.
The protective effect against hyperglycaemia by the treatment with
the IKKb-inhibitor was also reflected in HbA1C levels as these were
unchanged through the study.
It is not resolved as to whether the inhibitor treatment resulted
in a short-term effect on beta cell function as a result of a lower
demand for insulin due to increased insulin sensitivity, or if it has a
permanent effect on beta cell survival. However, during the 4 week
study, the animals treated with the IKKb-inhibitor showed no sign
of insulin depletion or beta cell failure. An early sign of beta cell
failure in P. obesus is decreased pancreatic insulin content, which
leads to decreased insulin production and reduced plasma insulin
levels [24,33]. When we analyzed pancreatic insulin content we
found an inverse relationship between pancreatic insulin stores
and blood glucose. We also found that animals treated with the
IKKb-inhibitor had significantly more pancreatic insulin content,
as demonstrated by extraction and immunohistochemistry.
The presented data demonstrates that the inhibition of the
NFkB pathway in vitro protects against beta cell failure and in vivo
protects against hyperglycaemia and decreased pancreatic insulin
content. Still, the in vivo effect on beta cell function could be a
secondary effect of increased insulin sensitivity which our
experiments did not investigate. However, previous studies have
demonstrated that inhibition of IKKb activity protects against
lowered insulin sensitivity. For instance, knock out of IKKb in
hepatocytes and myeloid cells have shown to protect high fat fed
mice against insulin resistance in both muscle, liver and fat
[16,34]. Furthermore, heterozygous deletion of IKKb also protects
against the development of insulin resistance both during high-fat
feeding and in obese Lep
ob/ob mice [18]. Non-steroidal anti-
inflammatory drugs such as aspirin and salicylate also have a
glucose lowering effect in both rodents and humans [2,18,29].
These drugs are cyclooxygenase but also function as non-selective
inhibitors of NFkB activity, which has been ascribed as the
mechanism connected to increased insulin sensitivity [17].
In summary, we have shown that the development of diet-
induced diabetes in P. obesus was prevented by treatment with a
selective IKKb-inhibitor. The IKKb-inhibitor also prevented
cytokine induced loss of insulin production and beta cell death
in primary islets and beta cells, possibly by inhibition of ROS
production. This was also reflected in vivo since treated animals had
much larger insulin reserves compared to the exhausted pancreata
in vehicle treated animals. In conclusion, these data support the
Figure 6. Effect of an IKKb-inhibitor on pancreatic insulin content in P. obesus. Diabetes-prone P. obesus, age of 13–14 weeks, were
transferred from ad libitum low energy diet to ad libitum high energy diet. At the same day (day 0) treatment was initiated with vehicle or with the
IKKb-inhibitor. A) Data shows blood glucose vs. pancreatic insulin content after 28 days of treatment with vehicle (open circles n=12) or with the
IKKb-inhibitor (black circles n=10); and from age matched non-diabetic animals feed ad libitum low energy diet (lean control) (open triangles n=8).
Immunostaining in reddish brown for insulin in tissue sections of pancreata from animals after 28 days of treatment with vehicle (B) or with the IKKb-
inhibitor (C); and from a age matched non-diabetic lean control animal (D).
doi:10.1371/journal.pone.0013341.g006
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diabetes.
Methods
IKKb-inhibitor
The IKKb-inhibitor was synthesized at Novo Nordisk A/S. The
structure and properties have been published by Ziegelbauer and
colleague [26]. In all in vitro experiments a pure form of the IKKb-
inhibitor was used whereas an enantiomeric mixture of the
compound was used in the in vivo assay. Ziegelbauer and colleague
[26] referred to the pure and the enantiomeric mixture of the
IKKb-inhibitor as COMPOUND A and COMPOUND B,
respectively.
Cell culture
A rat insulinoma cell line, INS-1 cells (a gift from Prof. Claes
Wollheim, Geneva [35]) was maintained in RPMI 1640 medium
with 11 mM glucose supplemented with 10% fetal bovine serum,
100 U/ml penicillin, 100 mg/ml streptomycin and 50 mM b-
mercaptoethanol (all from Gibco-BRL). For preparation of cell
culture for MTT, Caspase and insulin measurement, 50.000 cells/
well were seeded in 96-well poly-L-lysine coated (to insure
adherence) culture dishes (Cyto-well 96F. Nunc, Roskilde, Den-
mark). Two days after plating, the cells were pre-incubated for one
hour with the IKKb-inhibitor (0,5 or 0,1 mM) before IL-1b
(mouse IL-1b, Sigma) (50 or 150 pg/ml) were added. Following
exposure for the period of time indicated in the figures, insulin
secretion, viability (measured as MTT activity), caspase 3/7
activity and production of ROS were quantified. For RT-PCR,
1,5 mil cells/well were seeded in 6-well culture dishes (Nunc,
Roskilde, Denmark). Two days after plating, the cells were pre-
incubated for one hour with the IKKb-inhibitor (0,1 mM) before
IL-1b (150 pg/ml) was added. Cells were exposed for 24 hours
before RNA was extracted.
In vitro islet studies in isolated islets of Langerhans from
newborn Wistar rats
Pancreata from 3- to 5-day-old Wistar rats (Taconic, Ry,
Denmark) were collagenase-digested and the islets were isolated by
Percoll gradient purification (GE Healthcare, Denmark) as
previously described [36]. Islets were maintained in RPMI 1640
supplemented with 1% penicillin/streptomycin, 10% newborn calf
serum, 11 mM glucose (Gibco-BRL) and incubated in a 5% CO2
humidified atmosphere at 37uC. For the measurement of ROS,
about fifteen islets/well were cultured in 96-well poly-L-lysine
coated dishes (Cyto-well 96F), whereas 1000 islets/well were
cultured in 6-well dishes (Nunc, Roskilde, Denmark) for RT-PCR.
One day after plating, islets were pre-incubated for one hour with
the IKKb-inhibitor (0,1 mM) before incubation with IL-1b
(150 pg/ml) for another 24 hours.
In vitro islet studies in P. obesus
Isolated islets from healthy adult P. obesus on LE diet (Harlan;
Jerusalem, Israel) were handpicked, as described [37], and
incubated in RPMi 1640 supplemented with 1% penicillin/
streptomycin, 10% newborn calf serum and 5 mM glucose (Gibco-
BRL). About fifteen islets/well were cultured in extracellular
matrix coated 96-well plates (Biological Industries, Israel). After
5 hours, the islets were pre-incubated for one hour with the IKKb-
inhibitor (0,1 mM) followed IL-1b (2 ng/ml) (human IL-1b,
Sigma) exposure for 48 hours for ROS measurement, or 6 days
for Glucose-Stimulated Insulin Secretion (GSIS).
Cell viability and cell death
In INS-1 cells, viability was assessed by 3-4,5dimethylthiazol-
2,5diphenyl-tetrazolium bromide (MTT) assay (Promega) and cell
death by caspase 3/7 activity (Apo-ONEH Homogeneous
Caspase-3/7 Assay, Promega); both assays according to the
manufacturers instructions.
Insulin release
Before measurement of GSIS the culture media were collected
and frozen for quantification of accumulated insulin secretion. To
determine GSIS, the cells or islets were washed in Krebs-Ringer
buffer (115 mM NaCl, 4,7 mM KCl, 2,6 mM CaCl2, 1,2 mM
KH2PO4, 1,2 mM MgSO4, 5 mM NaHCO3, 10 mM HEPES,
0,2% BSA, pH 7.4) containing 3.7 mM glucose, and pre-
incubated for half a hour in the same buffer. The buffer was
replaced with a fresh buffer containing 3.7 mM glucose for one
hour before the buffer were collected (basal) and replaced with a
buffer containing 16.7 mM glucose for an additional one hour
(glucose stimulated). Supernatants were collected and frozen for
subsequent insulin determination; using a rat-specific lumines-
cence oxygen channeling immuno assay.
Measurement of intracellular ROS production
5-(and-6)-chloromethyl-29,79-dichloro-dihydrofluorescein diace-
tate (H2DCFDA) (Molecular probes) is a cell-permeable dye that
within the cells is cleaved by esterases to H2DCF. By the action of
different ROS (see Table 1) H2DCF is subsequently oxidized to its
fluorescent form [28]. At the indicated times cells or islets were
washed with DPBS (Gibco-BRL) and incubated in the dark with
10 mM fluorescent probe H2DCFDA in DPBS. Fluorescence was
measured on a NovoStar Microplate Reader (Ramcon, Denmark).
Results are shown as delta fluorescence (t90 min – t45 min).
Measurement of gene expression by real-time PCR
Cells were lysed in RLT buffer and islets in Qiazol Lysis
Reagent before RNA extraction according RNeasy protocol
(Qiagen). cDNA was transcribed using iScript cDNA Synthesis
Kit (Bio-Rad laboratories). Samples were assayed on an Mx3000
(Stratagene) using probs and primers designed by Probe Library
(Roche Diagnostics). The expression level of the gene of interest
was normalized to the housekeeping gene 36B4 and analyzed by
the DDCt method [38].
Animals
Male and female P. obesus, aged 7–9 weeks, were obtained from
Harlan (Israel). Animals were housed three per cage under
controlled conditions with a 12 hours light-12 hours dark cycle,
temperature of 25uC and fed low energy chow (LE-2.4 kcal/g;
Teklad, Jerusalem, Israel) and water ad libitum. At 10-11 weeks of
age animals were challenged with a high energy diet (HE-3.1kcal/g;
Purina 5008). Animals that showed sign of hyperglycaemia
(BG.10 mM) or no signs (BG,8 mM) during the test period of
10 days were classified as diabetes-prone animals or diabetic-
resistant animals, respectively. All animals were returned to LE diet.
At the age of 14–15 weeks all diabetes-prone animals were
normoglycemic again and transferred to an ad libitum high energy
diet. Animals were divided into two groups, treated orally with
either 2 ml/kg of either vehicle (10% 2-hydroxypropyl beta-
cyclodextrin in saline (HPCD/saline)) or the IKKb inhibitor
(60 mg/kg in HPCD/saline) every morning, for 4 weeks. During
this period body-weight (BW) was measured daily and morning
blood glucose (BG), HbA1C and insulin was measured one or two
times a week. The study was approved by the Animal Experiments
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2001/561-460).
Blood analysis
Blood samples was taken from the tail tip capillary into 10 ml
glass capillary tubes and immediately suspended in buffer (500 ml
of Biosen analysis buffer) and analysed for glucose on the test day
on a Biosen S_Line (EKF-diagnostic, GmbH). For HbA1C
measurement 5 ml was immediately suspended in 250 mlo f
Hitachi haemolysate buffer and analyzed on a Hitachi 912 (Roche
Diagnostics). For insulin measurement blood samples were taken
from the tail tip capillary into 80 ml capillary EDTA tubes and
immediately centrifugation at 5000 rpm for 5 minutes (at 4uC).
Plasma was collected and frozen until measurement of insulin
using a rat-specific luminescence oxygen channelling immuno
assay.
Pancreatic insulin content
At day 28 animals were anaesthetized by isoflurane before the
pancreas was removed as described above. Total pancreas was
weighted and sampled using ‘‘the smooth fractionator’’ technique
as earlier described [39]. Two thirds of the pancreas was
homogenized on a tissue-lyzer (Qiagen) at 25 Hz for 2 min in
acid-ethanol (30 mM HCl in 75% ethanol) using 1 ml/mg tissue.
The samples were placed on a rocker at 4uC overnight before
centrifuged at 200006ga t4 uC for one hour. Supernatants were
collected and the insulin concentration was quantified as described
above.
Pancreatic beta cell staning for insulin
One third of the pancreata from Psammomys obesus (sampled as
described above) were fixed in 4% paraformaldehyde, followed by
paraffin embedding. Sections were deparaffinized and rehydrated.
Endogenous peroxidase was blocked by submersion in 0.5% H2O2
for 20 minutes before washed in Tris-buffer saline (TBS) with
0,1% Tween 20 (TBS-T). The remaining steps were carried out in
an autostainer (DAKO Corp., Carpinteria, California, USA).
Sections were incubated 10 minutes with Avidin blocking solution
(DAKO) followed incubation for 10 minutes with Biotin blocking
solution (DAKO), with a washing procedure in TBS-T between
each step. Sections were incubated for 15 minutes with 10% rabbit
serum (X0902, DAKO) in TBS-T before stained for 60 minutes
for insulin with guinea pig anti-insulin serum (A0564, DAKO)
1:500 in 7% rabbit serum and 3% rat serum in TBS-T. Sections
were washed with TBS-T before incubated for 30 minutes with
peroxidise labelled rabbit anti-guinea pig (P0141, DAKO) 1:100 in
TBS-T. Peroxidise reactivity were developed for 12 minutes with
Nova Red (Vector laboratories, Burlingame, California, USA).
Sections were washed in tap water before counterstained for 15
seconds with haematoxylin, dehydrated and mounted with Pertex.
Statistical analysis
Data were analyzed with an unpaired t-test assuming equal
variances. If variances were found to be different between groups,
Welsh’s correction was applied. Results are represented as mean 6
SEM. p-values less than 0.05 are considered significant and are
indicated with *, while p-values of p,0.01 and p,0,001 are
marked with ** and ***, respectively.
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